MONMOUTH JUNCTION, N.J. , May 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company has been awarded a new preferred supplier agreement for CytoSorb® with the Asklepios Group (Asklepios), one of the largest private hospital operators in Germany , following the majority acquisition of RHÖN‑KLINIKUM AG in 2020.
CytoSorbents has entered into a 3-year preferred supplier agreement with Asklepios, making CytoSorb available without restrictions to all of the approximate 170 healthcare facilities across 14 states throughout Germany that Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany , which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery, and is well-known for their seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.
Dr. Christian Steiner , Executive Vice President, Sales and Marketing of CytoSorbents stated, "We are excited to announce this agreement with Asklepios, as we are now their preferred supplier of hemoadsorption technology. With this new agreement, CytoSorbents now has preferred supplier agreements with the three largest hospital chains in Germany , providing an opportunity to further grow our business. These privately owned hospital chains are always seeking value-added therapies that provide both clinical and economic benefit to ensure the highest quality medical care for their patients while supporting profitable operations. I am convinced CytoSorb is helping these hospital chains achieve both objectives."
About Asklepios Group Asklepios was established in 1985 and is now a leading private operator of hospitals in Germany . Asklepios' business activities have always been aimed at providing future-oriented medicine for patients based on the highest quality standards. Asklepios aspires to shape the future of medicine. One key to this lies also in digitalization. The Asklepios vision of a completely integrated digital healthcare group is summed up with the term "Digital HealthyNear". The Group currently has around 170 healthcare facilities throughout Germany represented in 14 German federal states functioning as a nationwide network for holistic healthcare provision. These include acute care hospitals of all different care levels, university hospitals, specialist hospitals, prevention and aftercare, rehabilitation clinics and medical centers. In the 2021 financial year over 3.5 million patients were treated at the Asklepios Group's facilities. The company has more than 67,000 employees. For more information consult www.asklepios.com.
About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been utilized as of December 31 , 2021. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company has initiated two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 30 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 30 center STAR‑D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine , representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022 , as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact: Terri Anne Powers Vice President, Investor Relations and Corporate Communications (732) 482-9984 tpowers@cytosorbents.com
U.S. Public Relations Contact: Eric Kim Rubenstein Public Relations 212-805-3052 ekim@rubensteinpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-awarded-preferred-supplier-agreement-with-asklepios-one-of-the-largest-private-hospital-operators-in-germany-301536980.html
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.
Although the two diseases share many symptoms, there are several key differences
"I can't fly a jet ... and clear the airspace," said Dr. David Brown, "but I do know who needs bandages and syringes and how to ask people for them."
To the public, the monkeypox outbreak has echoes of the early days of the COVID-19 pandemic. But scientists say it's not the same at all.
One day, doctors may be able to treat cataracts with a drug instead of surgery.
As summer rolls in and the weather heats up, many of us are looking to forward to indulging in our favorite pastime—going to the pool. According to the U.S. Bureau of Labor Statistics (BLS), swimming is the fifth-most popular activity in the U.S. That's hardly surprising, as there are 10.4 million residential and 309,000 public swimming pools in the country, Insider reports. But while a pool may seem safer than the ocean and the unknown creatures that roam it, swimming pools can also be hiding p
If you regularly reach for seed oils like canola oil, sesame oil or grapeseed oil when cooking -- or buy packaged foods that contain them -- listen up.
The company's protein-based shot has been authorized or approved in several other countries, including the U.K. and Singapore.
A Central Florida man survived what doctors call an “exploding heart.”
This groundbreaking study helps prove that eating breakfast, as well as what you eat for breakfast, can have a major impact on your health overall.
Americans are getting older and needing more colonoscopies. Private equity, seeing a “Golden Age of older rectums,” is buying up gastroenterology practices.
There is a clear disconnect across the U.S. in terms of the COVID pandemic right now. Some people are planning summer vacations, while others are masking back up as coronavirus cases start climbing back up. More than half of the U.S. population is still experiencing low virus transmission, but infections are rising, and many areas across the country have moved into medium and high levels of community spread, according to the Centers for Disease Control and Prevention (CDC). The agency's latest d
The accelerator program uses Target’s scale to help under resourced founders with access, education and resources.
Rowing is both a cardio and strength training workout that uses the whole body.
CDC identifies 9 monkeypox cases across 7 states
For instance, small-cap companies -- that is, those with market caps between $300 million and $2 billion -- tend to carry above-average risk. Let's look at two small-cap companies that could double your money within the next couple of years and deliver solid returns in the long run if they can navigate the road ahead: BioXcel Therapeutics (NASDAQ: BTAI) and Planet 13 Holdings (OTC: PLNH.F). The biotech currently boasts a market capitalization of $379 million and a share price of $11.75.